Bumi Citra Permai Tbk vs Prodia Diagnostic Line Tbk — how do they compare? Bumi Citra Permai Tbk trades at Rp62 (market cap 90.08B, 3.65M 24h volume), while Prodia Diagnostic Line Tbk trades at Rp270 (market cap 470.58B, 28.43M 24h volume). The key difference: Prodia Diagnostic Line Tbk is far larger — about 5.2× Bumi Citra Permai Tbk's market cap, and Prodia Diagnostic Line Tbk is more actively traded (28.43M versus 3.65M). Which is the better fit depends on your goals.
| BCIP | PRDL | |
|---|---|---|
Market Cap | 90.08B | 470.58B |
Volume | 3.65M | 28.43M |
Lot | 36.48K | 284.34K |
Turnover | 228.65M | 7.8B |
Average Price | 62.67 | 274.19 |
Value | 228.65M | 7.8B |
Indicative Equilibrium Price | 62 | 270 |
Indicative Equilibrium Volume | 1.79K | 2.1K |
Trailing returns across standard periods
Latest headlines on both assets
PT Bumi Citra Permai Tbk (the company) was established on 3 May 2000 based on Notaries Deed No. 2 and the deed of establishment was approved by the the Ministry of Justice dated Sep 7, 2000. The Company’s articles of association has been amended several times, most recently by notarial deed No. 9 of Robert Purba, S.H., dated 6 May, 2009, concerning among others, public offering and issue warrant.
Read more on BCIP →PT Prodia Diagnostic Line Tbk (the Company) was established April 16, 2010 with the name of PT DiaLine Systems Indonesia based on Notarial Deed No. 22 of Rismalena Kasri, S.H. On April 25, 2011, PT DiaLine Systems Indonesia changed the Companys name to PT Prodia Diagnostic Line based on Notarial Deed No. 14 of Rismalena Kasri, S.H. The Company is in the form of a Limited Liability Company in 2010 and began commercial production in 2011. The production results are marketed locally. The parent and ultimate parent entity of the Company is PT Prodia Utama.
Read more on PRDL →